Facing Challenges In Gene Therapy Development

Even the smallest decisions made at the outset of a gene therapy program can dramatically shape what follows. Early choices around vector design, target selection, manufacturing strategy, regulatory pathway, and clinical development don’t just influence timelines — they can determine the scale, cost, and complexity of every downstream challenge.

In this two-minute preview, we take a high-level look at the entire gene therapy development journey — from discovery and preclinical research to process development, manufacturing, regulatory engagement, and clinical trials. Along the way, we highlight the critical bottlenecks that often stand between promising science and successful patient delivery.

By understanding how early strategic decisions ripple across the development lifecycle, teams can better anticipate risks, avoid costly delays, and build more resilient, scalable programs from day one.